Market closed
Bausch Health/$BHC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Bausch Health
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Ticker
$BHC
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Laval, Canada
Employees
20,270
Website
Bausch Health Metrics
BasicAdvanced
$3B
Market cap
-
P/E ratio
-$0.49
EPS
0.77
Beta
-
Dividend rate
Price and volume
Market cap
$3B
Beta
0.77
52-week high
$11.46
52-week low
$3.96
Average daily volume
1.8M
Financial strength
Current ratio
1.188
Quick ratio
0.624
Long term debt to equity
-8,700
Total debt to equity
-8,887.19
Interest coverage (TTM)
1.22%
Management effectiveness
Return on assets (TTM)
4.04%
Return on equity (TTM)
90.99%
Valuation
Price to revenue (TTM)
0.316
Price to book
-2.57
Price to tangible book (TTM)
-0.17
Price to free cash flow (TTM)
2.966
Growth
Revenue change (TTM)
10.91%
Earnings per share change (TTM)
-81.60%
3-year revenue growth (CAGR)
3.88%
3-year earnings per share growth (CAGR)
-47.01%
What the Analysts think about Bausch Health
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Bausch Health stock.
Bausch Health Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Bausch Health Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Bausch Health News
AllArticlesVideos
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug
Reuters·4 days ago
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
Accesswire·4 days ago
Bausch Health Companies, Inc. (BHC) Q3 2024 Earnings Call Transcript
Seeking Alpha·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Bausch Health stock?
Bausch Health (BHC) has a market cap of $3B as of November 22, 2024.
What is the P/E ratio for Bausch Health stock?
The price to earnings (P/E) ratio for Bausch Health (BHC) stock is 0 as of November 22, 2024.
Does Bausch Health stock pay dividends?
No, Bausch Health (BHC) stock does not pay dividends to its shareholders as of November 22, 2024.
When is the next Bausch Health dividend payment date?
Bausch Health (BHC) stock does not pay dividends to its shareholders.
What is the beta indicator for Bausch Health?
Bausch Health (BHC) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.